

| | |
|----------------|-----------------------|
| type of report | Current report |
| number | 69/2013 |
| company | PHARMENA |

1-MNA extends lifespan in biological models of ageing

The Management Board of PHARMENA S.A informs that on 29th September 2013, the magazine Nature published a scientific study on the mechanisms of ageing processes. The research was done by world leading research centres, among others, by Swiss Federal Institute of Technology (ETH) Zurich, Switzerland, and Harvard Medical School, Boston, USA. The results of the conducted studies indicate the key role of 1-methylnicotinamide (1-MNA) in the processes of ageing. 1-MNA extends lifespan of organisms commonly used as biological models of human ageing. The said study is available on the Nature magazine's website:

<http://www.nature.com/nchembio/journal/vaop/ncurrent/full/nchembio.1352.html>

The information is made public due to the fact that 1-MNA is the subject of clinical trials on anti-atherosclerosis medicinal product. 1-MNA is also the subject of the process of authorisation as new food ingredient. Potential revenue after commercialisation of the above projects may prove to have significantly beneficial influence on the Issuer's financial and economic situation.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

Representatives of the company:

- Konrad Palka – President of the Board
- Marzena Wiczorkowska – Vice President of the Board